Literature DB >> 30108734

Thiosemicarbazone-based selective proliferation inactivators inhibit gastric cancer cell growth, invasion, and migration.

Biao Hu1, Bo Wang1, Bing Zhao1, Qian Guo1, Zhong-Hua Li1, Xin-Hui Zhang1, Guang-Yao Liu1, Ying Liu1, Ying Tang1, Fan Luo1, Ya Du1, Ya-Xin Chen1, Li-Ying Ma1, Hong-Min Liu1.   

Abstract

A series of novel thiosemicarbazone derivatives were synthesized and evaluated for their antiproliferative activity against several selected tumor cell lines of different origins using the MTT assay. The preliminary results indicated that the MGC-803 cell line was remarkably sensitive to all the synthesized compounds. Among this series, compound 5n showed the best inhibitory activity with an IC50 value of 0.93 μM (about 10-fold more potent than 3-AP) against MGC-803. Further mechanism studies revealed that compound 5n could obviously inhibit the proliferation of MGC-803 cells by inducing apoptosis and arresting the cell cycle at the S phase. Compound 5n also showed marked inhibition of cell migration and invasion, without significant cytotoxicity against gastric epithelial immortalized GES-1 cells.

Entities:  

Year:  2017        PMID： 30108734      PMCID： PMC6072408          DOI： 10.1039/c7md00353f

Source DB:  PubMed          Journal:  Medchemcomm        ISSN： 2040-2503            Impact factor:   3.597


  37 in total

Review 1.  Chelators at the cancer coalface: desferrioxamine to Triapine and beyond.

Authors:  Yu Yu; Jacky Wong; David B Lovejoy; Danuta S Kalinowski; Des R Richardson
Journal:  Clin Cancer Res       Date:  2006-12-01       Impact factor: 12.531

2.  Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.

Authors:  R A Finch; M Liu; S P Grill; W C Rose; R Loomis; K M Vasquez; Y Cheng; A C Sartorelli
Journal:  Biochem Pharmacol       Date:  2000-04-15       Impact factor: 5.858

3.  2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity.

Authors:  Des R Richardson; Danuta S Kalinowski; Vera Richardson; Philip C Sharpe; David B Lovejoy; Mohammad Islam; Paul V Bernhardt
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

4.  Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells.

Authors:  David B Lovejoy; Des R Richardson
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

5.  Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161).

Authors:  Jennifer J Knox; Sebastien J Hotte; Christian Kollmannsberger; Eric Winquist; Bryn Fisher; Elizabeth A Eisenhauer
Journal:  Invest New Drugs       Date:  2007-03-28       Impact factor: 3.850

6.  Berberine reverses epithelial-to-mesenchymal transition and inhibits metastasis and tumor-induced angiogenesis in human cervical cancer cells.

Authors:  Shu-Chen Chu; Cheng-Chia Yu; Li-Sung Hsu; Kuo-Shuen Chen; Mei-Yu Su; Pei-Ni Chen
Journal:  Mol Pharmacol       Date:  2014-09-12       Impact factor: 4.436

7.  Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo.

Authors:  David B Lovejoy; Danae M Sharp; Nicole Seebacher; Peyman Obeidy; Thomas Prichard; Christian Stefani; Maram T Basha; Philip C Sharpe; Patric J Jansson; Danuta S Kalinowski; Paul V Bernhardt; Des R Richardson
Journal:  J Med Chem       Date:  2012-08-03       Impact factor: 7.446

8.  A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.

Authors:  Judith E Karp; Francis J Giles; Ivana Gojo; Lawrence Morris; Jacqueline Greer; Bonny Johnson; Mya Thein; Mario Sznol; Jennifer Low
Journal:  Leuk Res       Date:  2007-07-20       Impact factor: 3.156

9.  Cellular confocal fluorescence studies and cytotoxic activity of new Zn(II) bis(thiosemicarbazonato) complexes.

Authors:  Sofia I Pascu; Philip A Waghorn; Timothy D Conry; Bonita Lin; Helen M Betts; Jonathan R Dilworth; Robert B Sim; Grant C Churchill; Franklin I Aigbirhio; John E Warren
Journal:  Dalton Trans       Date:  2008-03-18       Impact factor: 4.390

10.  Fluorescence studies of the intra-cellular distribution of zinc bis(thiosemicarbazone) complexes in human cancer cells.

Authors:  Andrew R Cowley; Jason Davis; Jonathan R Dilworth; Paul S Donnelly; Rachel Dobson; Adrian Nightingale; Josephine M Peach; Ben Shore; David Kerr; Len Seymour
Journal:  Chem Commun (Camb)       Date:  2005-01-21       Impact factor: 6.222
View more
  2 in total

1.  Enhanced anticancer potency with reduced nephrotoxicity of newly synthesized platin-based complexes compared with cisplatin.

Authors:  Roya Salehi; Selda Abyar; Fatemeh Ramazani; Ali Akbar Khandar; Seyed Abolfazl Hosseini-Yazdi; Jonathan M White; Mahdi Edalati; Houman Kahroba; Mehdi Talebi
Journal:  Sci Rep       Date:  2022-05-18       Impact factor: 4.996

2.  Discovery of thiosemicarbazone derivatives as effective New Delhi metallo-β-lactamase-1 (NDM-1) inhibitors against NDM-1 producing clinical isolates.

Authors:  Bing Zhao; Xinhui Zhang; Tingting Yu; Ying Liu; Xiaoling Zhang; Yongfang Yao; Xuejian Feng; Hongmin Liu; Dequan Yu; Liying Ma; Shangshang Qin
Journal:  Acta Pharm Sin B       Date:  2020-07-16       Impact factor: 11.413
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.